WA
SAGE

WFG Advisors’s Sage Therapeutics SAGE Stock Holding History

WFG Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$12K Hold
156
– – ﹤0.01% 1091
2017
Q1 		$11K Hold
156
– – ﹤0.01% 1047
2016
Q4 		$8K Hold
156
– – ﹤0.01% 1175
2016
Q3 		$7K Hold
156
– – ﹤0.01% 1225
2016
Q2 		$5K Hold
156
– – ﹤0.01% 1251
2016
Q1 		$5K Hold
156
– – ﹤0.01% 1203
2015
Q4 		$9K Hold
156
– – ﹤0.01% 1110
2015
Q3 		$7K Buy
+156
New +$9.61K ﹤0.01% 1190

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

WFG Advisors's SAGE Position: Q2 2017 in Review

WFG Advisors held its Sage Therapeutics (SAGE) position steady in Q2 2017 at 156 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

WFG Advisors first reported a position in SAGE in Q3 2015 and has held it in 8 quarters since. 191 funds tracked by Wall St. Rank hold SAGE as of Q2 2017.

  • WFG Advisors held 156 shares of Sage Therapeutics worth $12K as of Q2 2017.
  • WFG Advisors left its Sage Therapeutics share count unchanged in Q2 2017.
  • Sage Therapeutics made up ﹤0.01% of WFG Advisors's portfolio in Q2 2017, its #1091 holding.
  • WFG Advisors first reported a position in Sage Therapeutics in Q3 2015 and has held it in 8 quarters since.
  • 191 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2017.

Based on WFG Advisors's 13F filing for Q2 2017, filed 18 Aug 2017.